Cancer.im Inc. signed an exclusive agreement to commercialize a device that analyzes a small amount of urine for markers that are found in breast and other forms of cancer. This device and the use of biomarkers allow for rapid, point-of-care tests for early screening of cancer that noninvasively monitors levels of pteridine biomarkers in urine. Its unique design delivers superior sensitivity to mass spectrometry at a fraction of the cost of comparable analytical platforms. There are many other advantages to this technology.
News 
Market Data 
Discover 
